阿帕他胺用于中危前列腺癌的II期试验及分子相关性研究
这项单臂II期试验纳入40例中危前列腺癌患者,术前接受阿帕他胺240 mg/日共6个月后行根治性前列腺切除术。40%患者术后存在不良病理特征,3年生化复发率为15%,27.5%不可评估;术前阿帕他胺未使术后放疗风险降至预设阈值。转录组分析发现不良病理结局和生化复发与细胞周期及氧化磷酸化通路表达增高相关。
要点
- 术前阿帕他胺6个月后,40%患者存在不良病理特征,3年生化复发率为15%,27.5%不可评估。
- 术前阿帕他胺未使未选择中危前列腺癌患者的术后综合放疗风险降至预设阈值。
- 不良病理特征和3年生化复发与E2F靶点(Padj<0.001,NES 2.47)及氧化磷酸化(Padj<0.001,NES 1.62)通路表达增高相关。
核心结论
- 术前阿帕他胺未使未选择的中危前列腺癌患者的术后综合放疗风险降至预设阈值。
- 转录组分析识别出与不良病理结局和生化复发相关的关键失调通路,值得未来研究。
- 高危前列腺癌患者的术前治疗进一步研究正在进行中。
研究设计与样本
- 单臂II期试验,2018年5月至2020年2月纳入符合条件的中危前列腺癌患者(Gleason 3+4或4+3且临床T2b-c或前列腺特异性抗原10-20 ng/mL)。
- 患者接受阿帕他胺240 mg/日共6个月后行根治性前列腺切除术。
- 主要终点为术后存在任何需盆腔放疗的不良病理特征(新辅助治疗后病理T分期[yp]T3或ypN1或手术切缘阳性)。
- 对阿帕他胺治疗后根治性前列腺切除标本进行转化研究,包括胚系和体细胞DNA改变及RNA和蛋白表达,并评估其与临床结局的关联。
主要发现
- 共40例患者接受根治性前列腺切除术,仅1例在6个月前停用阿帕他胺。
- 40%的患者在根治性前列腺切除术时存在不良病理特征,3年生化复发率为15%,27.5%不可评估。
- 转移性前列腺癌中常见的基因组改变如雄激素受体(AR)、肿瘤蛋白p53(TP53)、磷酸酶和张力蛋白同源物(PTEN)或乳腺癌易感基因(BRCA1/2)在该局部队列中代表性不足。
- 不良病理特征和3年生化复发与特定细胞周期通路(如E2F靶点:校正P值[Padj]<0.001,标准化富集评分[NES]2.47)和氧化磷酸化通路(Padj<0.001,NES 1.62)表达增高相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine whether 6 months of preoperative apalutamide for intermediate-risk prostate cancer (IRPCa) reduces the aggregate postoperative radiotherapy risk and to evaluate associations of molecular perturbations with clinical outcomes in this study cohort. PATIENTS AND METHODS: Between May 2018 and February 2020, eligible patients with IRPCa (Gleason 3 + 4 or 4 + 3 and clinical T2b-c or prostate-specific antigen level of 10-20 ng/mL) were treated with apalutamide 240 mg/day for 6 months followed by radical prostatectomy (RP) in this single-arm, phase II trial. The primary endpoint was presence of any adverse pathological feature at risk of pelvic radiation (pathological T stage after neoadjuvant therapy [yp]T3 or ypN1 or positive surgical margins). Translational studies, including germline and somatic DNA alterations and RNA and protein expression, were performed on post-apalutamide RP specimens, and assessed for associations with clinical outcomes. RESULTS: A total of 40 patients underwent a RP, and only one patient discontinued apalutamide prior to 6 months. In all, 40% had adverse pathological features at time of RP, and the 3-year biochemical recurrence (BCR) rate was 15%, with 27.5% being not evaluable. Genomic alterations frequently seen in metastatic PCas, such as androgen receptor (AR), tumour protein p53 (TP53), phosphatase and tensin homologue (PTEN), or BReast CAncer associated gene (BRCA1/2) were underrepresented in this localised cohort. Adverse pathological features and BCR at 3-years were associated with increased expression of select cell cycle (e.g., E2F targets: adjusted P value [Padj] < 0.001, normalised enrichment score [NES] 2.47) and oxidative phosphorylation (Padj < 0.001, NES 1.62) pathways. CONCLUSIONS: Preoperative apalutamide did not reduce the aggregate postoperative radiation risk to the pre-specified threshold in unselected men with IRPCa. However, transcriptomic analysis identified key dysregulated pathways in tumours associated with adverse pathological outcomes and BCR, which warrant future study. Further investigation of preoperative therapy is underway for men with high-risk PCa.
引用
- Hahn AW, Manyam GC, Chapin BF, et al. A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU Int. 2024. PMID: 38837608. doi:10.1111/bju.16414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。